- Home
- MNPR vs IMRX Comparison
MNPR vs IMRX Comparison
Compare MNPR & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | IMRX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 340.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNPR | IMRX |
|---|---|---|
| Price | $53.06 | $6.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $107.00 | $17.20 |
| AVG Volume (30 Days) | 168.5K | ★ 699.7K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.99 | 37.75 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.40 | $1.10 |
| 52 Week High | $105.00 | $10.08 |
Technical Indicators
Market Signals| Indicator | MNPR | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 61.71 |
| Support Level | $50.77 | $6.00 |
| Resistance Level | $60.67 | $7.67 |
| Average True Range (ATR) | 3.03 | 0.35 |
| MACD | -0.32 | 0.05 |
| Stochastic Oscillator | 25.60 | 79.81 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.